Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Devotion: Journal of Research and Community Service Jurnal Sains dan Kesehatan
Irfan, Ihsanul
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Immunology & microbiology Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Devotion: Journal of Research and Community Service

 1 
Efficacy Of Ertugliflozin Compared With Metformin Or Placebo In Reducing Hba1c Levels Among Adults With Type 2 Diabetes: A Systematic Review And Meta-Analysis Permana, Galih Indra; Munthe, Ervi Audina; Irfan, Ihsanul
Devotion : Journal of Research and Community Service Vol. 6 No. 10 (2025): Devotion: Journal of Community Research
Publisher : Green Publisher Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59188/devotion.v6i10.25569

Abstract

Type 2 diabetes mellitus (T2DM) remains a global health challenge characterized by chronic hyperglycemia due to insulin resistance and impaired insulin secretion. Glycemic control, measured by glycated hemoglobin (HbA1c), is a crucial indicator of therapeutic effectiveness. This systematic review and meta-analysis aim to compare the efficacy of Ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, with Metformin and Placebo in reducing HbA1c levels among adults with T2DM. Relevant randomized controlled trials (RCTs) published between 2015 and 2025 were identified through PubMed, Scopus, and Cochrane databases. Data extraction and quality assessment followed PRISMA guidelines. The pooled analysis demonstrated that Ertugliflozin significantly reduced HbA1c levels compared to placebo, with mean differences ranging from −0.6% to −1.0% (p < 0.001). When compared to Metformin, Ertugliflozin showed comparable glycemic efficacy, with additional benefits in weight reduction and blood pressure control. Heterogeneity among studies was moderate (I² < 50%), and no severe adverse effects were reported. These findings suggest that Ertugliflozin is an effective and safe alternative or adjunct therapy for adults with T2DM, offering multifaceted metabolic benefits beyond glucose control.
Co-Authors Bakring, Abi Galih Indra Permana Munthe, Ervi Audina